Physician profile
Sofya Pintova
NPI 1760737720
$54,743.52
in general payments reported to CMS, 2019-2025
16 companies · $383 in 2025
The $383 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,946 · 2022: $8,989 · 2023: $32K · 2024: $7,945 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Consulting Fee: $10K · Food and Beverage: $1,497 · Travel and Lodging: $1,472 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,540.00 |
| Consulting Fee | $10,180.00 |
| Food and Beverage | $1,496.82 |
| Travel and Lodging | $1,471.62 |
| Education | $119.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $42,033.96 | 2022-2025 | Imfinzi |
| Merck Sharp & Dohme LLC | $5,479.81 | 2023-2024 | Keytruda |
| Tesaro, INC. | $4,908.97 | 2019 | |
| Taiho Oncology, INC. | $1,980.00 | 2023 | |
| Exelixis INC. | $99.99 | 2023 | |
| Beone Medicines USA, INC. | $72.20 | 2025 | Tevimbra |
| Astellas Pharma US INC | $52.35 | 2025 | Vyloy |
| Celgene Corporation | $37.08 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.85 | 2025 | |
| Emd Serono, INC. | $21.61 | 2022 | |
| Array Biopharma INC | $19.64 | 2024 | Lorbrena, Braftovi |
| Daiichi Sankyo INC. | $16.06 | 2025 | Enhertu |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofya Pintova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.